Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

2019 ◽  
Author(s):  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Low Dose ◽  
Advanced Chronic Kidney Disease

Indoxyl Sulfate Predicts Cardiovascular Disease and Renal Function Deterioration in Advanced Chronic Kidney Disease

2012 ◽  
Vol 43 (6) ◽  
pp. 451-456 ◽  
Author(s):  
Cheng-Jui Lin ◽  
Hsuan-Liang Liu ◽  
Chi-Feng Pan ◽  
Chih-Kuang Chuang ◽  
Thanasekaran Jayakumar ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Indoxyl Sulfate ◽  
Advanced Chronic Kidney Disease ◽  
Renal Function Deterioration

scholarly journals A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease

Heart ◽  
2017 ◽  
Vol 103 (23) ◽  
pp. 1880-1890 ◽  
Author(s):  
Iryna Schlackow ◽  
Seamus Kent ◽  
William Herrington ◽  
Jonathan Emberson ◽  
Richard Haynes ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Advanced Chronic Kidney Disease ◽  
Policy Model

scholarly journals Low-Dose Aspirin for Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e104179 ◽  
Author(s):  
Ae Jin Kim ◽  
Hye Jin Lim ◽  
Han Ro ◽  
Kwang-Pil Ko ◽  
Song Yi Han ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Low Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Prevention Of Cardiovascular Disease

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

Sign in / Sign up

Export Citation Format

Share Document